Does United Healthcare Cover Inspire? Criteria, Costs, and Denials

UnitedHealthcare does cover Inspire therapy for obstructive sleep apnea, classifying the implanted hypoglossal nerve stimulator as proven and medically necessary when the patient meets a specific set of clinical criteria. Approval is not automatic. Every case goes through prior authorization, and missing even one requirement, such as the BMI ceiling or the sleep study thresholds, is enough for a denial.

Inspire is a small surgically implanted device that stimulates the hypoglossal nerve to keep the airway open during sleep. The FDA first approved it in 2014, and later approvals extended its use to adolescents with Down syndrome.

Adult Eligibility Criteria

Under UnitedHealthcare’s commercial and individual exchange medical policy effective January 1, 2026, an adult must meet all of the following for Inspire to be considered medically necessary:

  • Body mass index of 40 or below.
  • Apnea-hypopnea index (AHI) between 15 and 100, measured by in-lab (attended) polysomnography.
  • Central and mixed apnea events accounting for less than 25 percent of the total AHI.
  • A drug-induced sleep endoscopy (DISE) confirming the absence of complete blockage or complete concentric collapse at the soft palate level.
  • Documentation that positive airway pressure (PAP) therapy provided no benefit, or that the patient could not tolerate it or refused it.
  • Use of the device consistent with FDA-approved guidelines.

The BMI and AHI numbers are the clearest disqualifiers. The DISE finding and the CPAP documentation involve more clinical judgment and are the places where providers most often need to build a careful record. An earlier version of the policy, revised in March 2024, briefly required an adequate trial of oral appliance therapy before surgical treatment. The current January 2026 policy does not include that step; documented PAP failure, intolerance, or refusal is enough.

Adolescents With Down Syndrome

UnitedHealthcare’s policy extends coverage to patients aged 10 through 18 who have Down syndrome and severe obstructive sleep apnea. The criteria for this group are more involved:

  • AHI of 10 or higher and a respiratory disturbance index (RDI) of 50 or fewer events per hour.
  • BMI below the 95th percentile for the patient’s age.
  • Central and mixed events accounting for less than 25 percent of total AHI.
  • A contraindication to adenotonsillectomy, or prior adenotonsillectomy without adequate improvement.
  • Confirmed failure or intolerance of PAP therapy despite attempts to improve compliance.
  • No tracheostomy use for sleep.
  • DISE confirming no complete concentric collapse at the soft palate.
  • Patient and caregiver refusal of a maxillomandibular advancement (MMA) procedure for non-concentric palatal collapse.

UnitedHealthcare added this pathway in its March 2024 policy revision, following the FDA’s expanded approval for younger patients with Down syndrome.

What UnitedHealthcare Will Not Cover

The policy classifies implantable neurostimulation devices for central sleep apnea as unproven and not medically necessary. Patients whose apnea is primarily central rather than obstructive will not qualify for Inspire under this policy. UnitedHealthcare also lists non-surgical electrical muscular training, positional OSA devices, nasal dilators, and intranasal expiratory resistance valves as unproven for sleep apnea treatment.

Medicare Advantage Plans Through UHC

Medicare Advantage plans administered by UnitedHealthcare must follow Medicare coverage determinations. Every Medicare Administrative Contractor has issued a positive local coverage determination for Inspire, so the procedure is covered, though the Advantage plan may still impose its own prior authorization.

Medicare’s clinical thresholds are tighter than UHC’s commercial policy. The BMI limit is 35 rather than 40, the AHI range is 15 to 65 rather than 15 to 100, and the patient must be at least 22 years old. Medicare also requires the implanting surgeon to be a board-certified or board-eligible otolaryngologist who has completed manufacturer-specific training. A separate federal initiative, WISeR, began requiring AI-reviewed prior authorization for certain Medicare procedures in six pilot states in January 2026 and has caused some authorization delays.

UnitedHealthcare Community Plan (Medicaid)

UnitedHealthcare’s Community Plan, which runs Medicaid managed care in many states, covers Inspire under criteria that mirror the commercial policy. Adults face the same BMI, AHI, PAP failure, and DISE requirements, and adolescents with Down syndrome qualify under the same expanded criteria.

The Community Plan does not apply in every state. Eleven states follow their own guidelines rather than the UHC national Community Plan policy: Idaho, Indiana, Kansas, Kentucky, Nebraska, New Jersey, New Mexico, North Carolina, Ohio, Pennsylvania, and Tennessee. Medicaid members in those states should check their specific plan rules.

How Prior Authorization Works

Each commercial Inspire case goes through prior authorization. According to Inspire Medical Systems, “for commercial payers each case is prior authorized,” which the company says helps reduce payment uncertainty for surgical centers. The process generally runs in three steps:

  • Candidacy screening. An online tool on the Inspire website compares a patient’s age, BMI, AHI, and CPAP history against more than 90 payer policies, including UnitedHealthcare’s.
  • Provider submission. The surgeon’s office compiles and submits the clinical record to UnitedHealthcare, including the sleep study, CPAP trial documentation, and DISE findings.
  • Review timeline. Prior authorization decisions typically take one to four weeks.

Inspire Medical Systems also runs an in-house support team that helps providers through the authorization process. The contact address is priorauthorizationsupport@inspiresleep.com. Traditional Medicare, unlike commercial UHC, does not require or allow prior authorization for Inspire outside the WISeR pilot states.

What Inspire Costs With UnitedHealthcare

UnitedHealthcare’s medical policy does not publish copay, coinsurance, or deductible amounts. Those depend entirely on the specific benefit plan. A few benchmarks help with planning.

Without insurance, total implantation cost is estimated at $30,000 to $40,000 or more, covering the device, surgeon fees, hospital or facility charges, anesthesia, and routine post-operative programming visits. The device alone has an estimated manufacturer price of about $23,100. Hospital-negotiated prices with insurers run from roughly $28,000 to more than $60,000, with a median markup of about 88 percent over the manufacturer price, according to a 2022 analysis of payer-negotiated hospital pricing.

For Medicare patients, reported out-of-pocket costs run from about $1,796 to $5,133 after Medicare Part B pays its standard 80 percent, varying by facility setting and other plan factors. For a commercial UHC member, the actual out-of-pocket figure depends on remaining deductible, coinsurance, and the out-of-pocket maximum. In-network status for the surgeon, facility, and anesthesiologist can change the final bill substantially. Request an itemized benefits check confirming in-network status for every billing party before scheduling.

If UnitedHealthcare Denies Coverage

Most denials come down to a clinical criterion that was not met: BMI above 40, AHI outside the 15-to-100 range, insufficient CPAP failure documentation, or a DISE result showing complete concentric collapse at the soft palate. The policy also warns that meeting every clinical criterion “does not guarantee coverage of the service requested,” because the member’s benefit plan document controls the final decision.

UnitedHealthcare’s medical policy does not spell out an appeals process specific to Inspire. The denial letter and explanation of benefits will state the reason for denial and the instructions for appeal. Members can request a redetermination through UHC and, if that is unsuccessful, escalate to an independent external review. The number on the back of the insurance card reaches UnitedHealthcare directly to discuss the denial and the next step.